This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| STZ | |
|---|---|
| Name | STZ |
| Caption | Structural representation |
| Othernames | Streptozotocin |
| Formula | C8H15N3O7 |
| Molarmass | 265.22 g·mol−1 |
STZ Streptozotocin is a naturally derived nitrosourea compound used in biomedical research and medicine. It appears in studies spanning Banting-era diabetes models, Ketoacidosis research, and oncology clinical trials such as those led at Johns Hopkins Hospital and Mayo Clinic. Researchers from institutions including Harvard University, University of Oxford, Karolinska Institutet, and Massachusetts Institute of Technology have characterized its chemistry, pharmacology, and toxicology.
The trivial name derives from its origin: an antibiotic-related compound first isolated by investigators associated with Eli Lilly and Company and the University of Wisconsin–Madison pharmaceutical microbiology groups in the mid-20th century. Common abbreviations include STZ (widely used in literature from Nature and Science) and streptozocin (appearing in archives of the New England Journal of Medicine). Historic correspondence among researchers at Merck & Co., Bayer AG, and academics at Columbia University helped standardize the nomenclature in pharmacopeias and regulatory filings with agencies such as the U.S. Food and Drug Administration.
STZ is a glucose analogue conjugated to a nitrosourea moiety; its empirical formula and stereochemistry were determined using techniques popularized by groups at Caltech and ETH Zurich. The compound has polar functional groups that confer solubility characteristics measured in studies from DuPont laboratories and reported in chemical handbooks used at Imperial College London. Spectroscopic characterization (infrared, NMR, mass spectrometry) was performed in collaborative work involving Rutherford Appleton Laboratory and Lawrence Berkeley National Laboratory, confirming the presence of a methylated N-nitrosourea and a hexose-derived fragment. Crystallographic and thermochemical studies cited by researchers at University of Cambridge provide melting point, solubility, and stability data used in handling guidelines at Stanford University facilities.
Initial isolation and production routes trace to fermentation-derived metabolites studied by teams at Eli Lilly and Company and Pfizer. Synthetic routes were later optimized in synthetic organic chemistry programs at Princeton University and University of California, Berkeley, employing nitrosation of urea precursors and glycosylation strategies developed in collaboration with Max Planck Society chemists. Industrial-scale production methods adapted by Bristol-Myers Squibb and contract manufacturers follow Good Manufacturing Practice standards promoted by World Health Organization and European Medicines Agency guidelines. Purification and quality control procedures use analytical protocols from American Chemical Society-affiliated laboratories and instrumentation from Agilent Technologies and Bruker.
STZ exhibits selective toxicity toward pancreatic β-cells, a phenomenon elucidated in classic experiments at University of Pennsylvania and University of Chicago. Entry into β-cells exploits glucose transporter proteins, notably interactions inferred from studies of GLUT2 published by teams at Yale University and University of Tokyo. Once internalized, the N-nitrosourea moiety causes DNA alkylation and single-strand breaks; DNA damage response pathways described by researchers at Cold Spring Harbor Laboratory and Howard Hughes Medical Institute activate poly(ADP-ribose) polymerase enzymes explored in work at Salk Institute and National Institutes of Health. These biochemical cascades can trigger necrosis and apoptosis, as detailed in comparative studies from Fred Hutchinson Cancer Center and Dana-Farber Cancer Institute.
Clinically, STZ has been evaluated in oncologic settings for tumors such as pancreatic islet cell neoplasms in trials coordinated by MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Pharmacokinetic and pharmacodynamic profiling has been performed using assays developed at GlaxoSmithKline and Roche research units. Toxicological profiles include nephrotoxicity and hepatotoxicity described in regulatory submissions to the U.S. Food and Drug Administration and adverse event reports compiled by World Health Organization pharmacovigilance. Dose-dependent effects on fertility and mutagenicity were assessed in studies conducted at National Toxicology Program laboratories and summarized in monographs from European Medicines Agency committees.
STZ is widely used to create experimental models of diabetes mellitus by inducing β-cell loss in rodents and larger mammals; foundational model descriptions originate from investigators at University of California, San Francisco and University of Toronto. These models are routinely used in preclinical investigations at Scripps Research and Mount Sinai Hospital to test interventions ranging from islet transplantation (techniques refined at Cleveland Clinic) to regenerative approaches reported from NIH-funded consortia. Oncology researchers at Memorial Sloan Kettering Cancer Center and Vanderbilt University Medical Center use STZ in studies of chemotherapy resistance and DNA repair. Imaging and biomarker studies employ platforms developed at Johns Hopkins University and Massachusetts General Hospital.
Therapeutic approvals and labeling decisions have been issued by regulatory authorities including the U.S. Food and Drug Administration, European Medicines Agency, and national agencies in Japan and Australia for specific oncologic indications. Handling, storage, and disposal guidance align with standards from Occupational Safety and Health Administration and National Institutes for Occupational Safety and Health protocols; institutional biosafety committees at University of Michigan and UCLA implement local controls. Clinical trial oversight involves ethics review boards modeled on frameworks from Council for International Organizations of Medical Sciences and Declaration of Helsinki principles. Category:Chemicals